Open in new window
|
|
|
Pharmaindustrial News
|
|
United Imaging Receives FDA Clearance for uMR Jupiter 5T MRI System
The uMR Jupiter is hailed as the first ultra-high field system cleared for whole-body applications, setting a new standard in the field.
Read more
|
|
|
Medison Pharma and Alnylam Pharmaceuticals Expand Partnership to Reach More Patients Globally
Medison has developed a unique commercialization platform focused on delivering cutting-edge treatments for rare and severe diseases.
Read more
|
|
|
First Infant Pyeloplasty Done Using SSi Mantra Surgical Robotic System
SS Innovations International has announced the successful performance of the first pyeloplasty procedure performed on an infant utilizing its flagship SSi Mantra Surgical Robotic System.
Read more
|
|
|
TriLink Signs Non-Exclusive License and Supply Agreement with Lonza
TriLink BioTechnologies has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
Read more
|
|
|
INCOG Facility Receives FDA Approval for Commercial Drug Production
INCOG BioPharma Services has announced that its sterile injectable manufacturing facility has received approval from the US Food and Drug Administration (FDA) to produce a commercially approved drug...
Read more
|
|
|
AEYE Health Receives FDA Clearance for Autonomous AI Diagnosis of Diabetic Retinopathy
AEYE-DS is the sole solution enabling screenings with just one image per eye, boasting over 99 percent imageability.
Read more
|
|
|
Ingenium Therapeutics' Investigational NK Cell Therapy Granted Orphan Drug Designation for AML Treatment
This allogeneic NK cell therapy, derived from healthy donors, exhibits potent anti-cancer effects characterized by high purity and activity.
Read more
|
|
|
Bayer and Evotec to Upgrade Precision Cardiology
Bayer and Evotec have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs).
Read more
|
|
Interviews
|
|
TheWell Bioscience Tailoring Solutions for Biopharma with Synthetic Hydrogels
Kindly shed some light about the development process of your xeno-free hydrogel system (VitroGel) and how it closely mimics the natural extracellular matrix?
The...
Read more
|
|
|
|
This message and any attachments are confidential and privileged and intented for the use of the addressee only. If you have received this communication in error, please notify the sender by replay e-mail and delete this message from your system. Please note that Internet e-mail guarantees neither the confidentiality nor the proper receipt of the message sent. The data deriving from our correspondence with you are included in a file of OMNIMEDIA, S.L. which exclusive purpose is to manage the communications of the company; under the understanding that, in maintaining said correspondence, you authorize the treatment of such data for the mentioned purpose. You are entitled to exercise your rights of access, rectification, cancellation and opposition by addressing such written application to address C/ Pollensa, 2, Edif. Artemisa of. 12 de LA ROZAS (28290 - MADRID) enclosing your NIF or identifying document photocopies of.
Unsubscribe
|